# Special Issue

# Immunological Insights into Multiple Sclerosis

# Message from the Guest Editors

Multiple sclerosis (MS) is a complex autoimmune disease characterized by the immune system attacking the central nervous system (CNS), leading to demyelination and neurodegeneration. Understanding the immunological underpinnings of MS is crucial for developing effective treatments and improving patient outcomes. This Special Issue aims to gather cuttingedge research and comprehensive reviews that delve into the immunological aspects of MS. We welcome contributions that explore the roles of various immune cells (such as T cells, B cells, and microglia), cytokines, and other molecular mediators in the pathogenesis of MS. Studies that address the interplay between genetic and environmental factors, the impact of immune system modulation therapies, and the development of novel immunotherapies are particularly encouraged. This collection will provide a deeper understanding of the immunology of MS, potentially guiding future therapeutic strategies and enhancing our ability to manage this challenging disease.

# **Guest Editors**

Prof. Dr. Georges E. R. Grau

Vascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Dr. Manisha Patil

Vascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

## Deadline for manuscript submissions

closed (20 May 2025)



# **Sclerosis**

an Open Access Journal by MDPI



mdpi.com/si/213602

Sclerosis
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
sclerosis@mdbi.com

mdpi.com/journal/ sclerosis





# **Sclerosis**

an Open Access Journal by MDPI





# Message from the Editor-in-Chief

Welcome to Sclerosis.

Sclerosis is a term that encompasses various conditions that involve the stiffening and scarring of tissues and organs. It is a pathologic process of some highly prevalent diseases, such as multiple sclerosis, glomerulosclerosis, atherosclerosis, and more rare diseases, such as amyotrophic lateral sclerosis, systemic sclerosis, and tuberous sclerosis.

Sclerosis aims to provide a platform for dissemination of cutting-edge research and clinical practice in the field.

Looking to similarities and differences among "sclerotic" diseases, we aim at identifying shared pathological mechanisms and risk factors, management pathways, and drugs with repurposing potential, while also exploring preventive and therapeutic strategies.

# Editor-in-Chief

Dr. Maurizio A. Leone

- Scientific Direction, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
- 2. Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy

#### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 37.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

# **Recognition of Reviewers:**

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

